

Figure S1. Incremental cost-effectiveness ratio for newborn screening for Pompe disease by cost of alglucosidase alfa (ERT), \$/QALY




Abbreviations: ERT, enzyme replacement therapy; QALY, quality adjusted life year; AWP, average wholesale price.

Figure S2. Health state probabilities^a


a. Infantile-onset Pompe disease with cardiomyopathy, clinically identified and treated




c. Infantile-onset Pompe disease with cardiomyopathy, newborn screened and treated



b. Infantile-onset Pompe disease without cardiomyopathy, clinically identified and treated



d. Infantile-onset Pompe disease without cardiomyopathy, newborn screened and treated



^aTrajectories determined using the transition probabilities outlined in Table S5.

Table S1. Epidemiology and probabilities of screening and diagnostic outcomes for Pompe disease, by identification and treatment scenario

Input	Base	Low	High	Source
Epidemiology				
Incidence of Pompe disease (annual, per 100,000)	2.5	1	2.5	1
Screening test characteristics				
Sensitivity	0.9322	0.9315	0.9329	2, expert
				opinion
Specificity	0.9999	-	-	
Screening and diagnostic outcomes				
Newborn screening				
Probability of initial positive test	0.000065533	0.000033507	0.000733532	3, assumption
Probability of positive test on confirmatory testing	0.5117	1	0.045747884	
Probability of false negative test on initial test	0.00000244	0.000002464029	0.00000241	
Among confirmed positives				
Probability of infantile-onset Pompe disease	0.298	0.226	0.384	1, 3, 4
Conditional probability of infantile-onset with	0.85	0.702	0.943	Expert
cardiomyopathy				opinion
Conditional probability of infantile-onset without	0.15	0.057	0.298	
cardiomyopathy	0.447	0.005	0.500	
Probability of late-onset Pompe disease	0.417	0.335	0.502	1, 3, 4
Probability of probable late-onset Pompe disease (healthy)	0.285	0.115	0.439	
Among false negatives				
Probability of infantile-onset Pompe disease	0.000	0.000	0.036	Assumption ^a
Probability of late-onset Pompe disease	0.417	0.335	0.502	
Probability of probable late-onset Pompe disease (healthy)	0.583	0.462	0.665	
Clinically identified and treated				
Probability of Pompe disease	0.000025	0.000001	0.000025	1
	0.4	0.303	0.503	1, 3, 4, expert
Conditional probability of infantile-onset Pompe disease	0.05	0.000	0.150	opinion
Conditional probability of infantile-onset without cardiomyopathy/treated	0.05	0.006	0.169	5,expert opinion
Conditional probability of infantile-onset without	0.10	0.000	0.292	Оринон
cardiomyopathy untreated	3.10	0.555	0.232	
Conditional probability of infantile-onset with	0.85	0.702	0.943	
cardiomyopathy				
	0.6	0.497	0.697	1, 3, 4, expert
Conditional probability of late-onset Pompe disease				opinion

Table S1 cont. Epidemiology and probabilities of screening and diagnostic outcomes for Pompe disease, by identification and treatment scenario

Input	Base	Low	High	Source
Clinically identified and untreated				
Probability of Pompe disease	0.000025	0.000001	0.000025	1
	0.4	0.303	0.503	1, 3, 4, expert
Conditional probability of infantile-onset Pompe disease				opinion
Conditional probability of infantile-onset with cardiomyopathy	0.85	0.702	0.943	5,expert opinion
Conditional probability of infantile-onset without cardiomyopathy	0.15	0.057	0.298	
	0.6	0.497	0.697	1,3, 4,expert
Conditional probability of late-onset Pompe disease				opinion

^aAssumed to be the same as clinically identified and untreated.

- [1] Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163:498-503.
- [2] Kemper AR, Comeau AM, Green NS, Goldenberg A, Ojodu J, Prosser LA, et al. Evidence report: newborn screening for pompe disease [cited 2018 November] Available from: https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf
- [3] Chiang S-C, Hwu W-L, Lee N-C, Hsu L-W, Chien Y-H. Algorithm for Pompe disease newborn screening: Results from the Taiwan screening program. Mol Gen Met. 2012;106:281-6.
- [4] Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335-41.
- [5] Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671-6.

Table S2. Cost inputs

a. Cost inputs, per person

Cost Inputs (annual, 2016 \$) ^a	Base	Low	High	Source
Screening test for Pompe disease per child	\$6.40	\$6.40	\$17.5	Personal
				communication ^b
Genetic and other confirmatory tests for	\$2,382	\$1,802	\$3,300	1, personal communication ^c
those who screen positive				
Enzyme replacement treatment ^d				
Age 1	\$75,475	\$71,828	\$117,624	2
Age 5	\$135,856	\$129,290	\$211,723	
Age 10	\$256,616	\$244,214	\$399,922	
Age 15	\$407,567	\$387,869	\$635,170	
Age 25	\$483,043	\$459,697	\$752,794	
Age 50	\$513,233	\$488,428 to	\$799,843	
Enzyme replacement therapy delivery ^e	\$14,300	\$10,882	\$96,000	3
Non-Pompe disease related medical costs				
	Varies by age	\$1,162	\$6,014	4
Probable Pompe disease, asymptomatic				
Watchful waiting ^f	\$437	-		1, 5
Appointment time ^g	\$51	-		6
Pompe disease, mild symptoms				
Medical costs (all)	Varies by age	\$7,303	\$14,257	1, 7, expert opinion h
Informal caregiving	\$18,928	\$12,915	\$18,928	8, 9 ⁱ
Appointment time	\$2,160	\$1,490	\$2,160	j
Transition to mild health state ^k	\$19,260			101
Pompe disease, severe symptoms				
Medical costs (all)	Varies by age	\$84,367	\$90,476	11, 1, expert opinion ^h
Formal caregiving	\$87,360	\$57,512	\$87,360	m
Informal caregiving	\$151,424	\$103,318	\$151,424	9 ⁿ
Appointment time	\$0			0
Transition to severe health state p	\$59,808	\$38,892	\$66,681	7

^a All costs were adjusted to 2016 dollars using the Gross Domestic Product price deflator

^b Correspondence with New Jersey, New York, Michigan, and Missouri newborn screening programs

^c Estimates from Greenwood Genetics Center, Emory University, Prevention Genetics, Baylor, Gene Dx, Cincinnati Children's Hospital, Seattle Children's Hospital, Duke University, LabCorp, Mayo Clinic, and Michigan Medicine Genetics Laboratories.

^d A one time cost of \$7,594 for immune tolerance induction was also applied in the first year of life to 25% of those with infantile-onset Pompe disease and cardiomyopathy. For more details see Table S2d. Redbook wholesale acquisition cost with a 23% discount was used for the base case. Lower bound estimate represents government-negotiated price; upper bound estimate reflects average wholesale price. CDC weight projections¹² were used for dosage estimates (we assumed those with Pompe disease are 95% of the national average weight), assuming 26 doses/year of 20 mg/kg; see Table S2c, for details.

^e Estimated price for home and hospital infusion (CMS Physician Fee Schedule price was not available for home infusion); assumes ERT infusion lasts 6 hours; first year 50%-75% assumed to occur at home and after that 100% at home; range based on CMS Physician Fee Schedule and expert opinion; see Table S2d, for details.

f Additional health care utilization for patients diagnosed with Pompe disease but without symptoms, annual estimate: 1 additional outpatient visit; lab work including creatine kinase-MB, comprehensive panel, and urine hex4 test

^g Visits were assumed to take 2 hours⁶, multiplied this by the US average hourly earnings⁹ of \$25.71

^h Types of services derived from Kishnani et al 2006 ⁷; number of services determined in consultation with a genetic counselor; costs assigned according to the CMS Physician Fee Schedule¹; see Table S2f for micro-costing details

¹14 hours of informal care per week multiplied by average hourly earnings⁹ of \$25.71

¹42 extra medical appointments, each requiring 2 hours of time⁶; multiplied by the US average hourly earnings⁹; estimates for transportation costs were not available and have not been included

- ^m 8 hours per day 7 days per week, at a wage of \$30 per hour; this wage reflects a combination of nurse and home health provider wages¹³; distribution determined by expert opinion.
- ⁿ 16 hours per day 7 days a week multiplied by the US average hourly earnings⁹
- ° Assuming these individuals are not engaged in productive activities and therefore would not incur opportunity costs for appointments
- ^p Wheel chair equipment and environmental changes: derived from data on patients with a spinal cord injury resulting in complete or partial paralysis ¹⁰ Cost also includes gastronomy costs.

^k Includes environmental modifications/renovations; extra medical equipment including wheelchair and other assistive devices. Also includes gastrostomy for transition to severe health state.

Derived from DeVivo et al (2011)¹⁰ which reported time costs for a patient with a spinal cord injury resulting in incomplete motor function

b. Cost of genetic and other confirmatory tests

Cost input	Base	Low	High	Source
Genetic tests				
GAA enzyme test ^a	\$86	\$11	\$263	Primary data analysis ^b
GAA sequencing test ^c	\$1,193	\$1,115	\$1,351	
GAA deletion/duplication test ^d	\$556	\$263	\$1,027	
Percent receiving GAA	10%	5%	15%	Assumption
deletion/duplication test				
Procedures				
Chest X-ray	\$46	\$23	\$69	1
Electrocardiogram	\$17	\$17	\$17	
Echocardiogram	\$450	\$240	\$659	
Electromyography	\$246	\$246	\$246	
Lab tests				
Creatine kinase-MB	\$12	\$9	\$20	5
Comprehensive Panel	\$19	\$14	\$32	
Urine Hex4	\$69	\$43	\$148	

^a GAA (acid-α-glucosidase) enzyme test is performed twice, CPT 82657

^b MarketScan analysis of 2016 data

^c CPT 81406

^d Charges reported by Greenwood Genetics Center, Emory University, Prevention Genetics, Baylor, Gene Dx, and Cincinnati Children's Hospital. Assumed 52.7% cost/charge ratio.

c. Cost of alglucosidase alfa^a

Age	Average weight	Number of Units Every 2	Annual		
(years)	(kg) ^b	weeks ^c	Cost ^d	Lower Estimate ^e	Upper Estimate ^f
<1	7.1	3	\$45,285	\$43,097	\$70,574
1	10.5	5	\$75,475	\$71,828	\$117,624
2	13.0	6	\$90,570	\$86,193	\$141,149
3	15.2	7	\$105,666	\$100,559	\$164,674
4	17.2	8	\$120,761	\$114,924	\$188,198
5	20.1	9	\$135,856	\$129,290	\$211,723
6	22.8	10	\$150,951	\$143,655	\$235,248
7	25.4	11	\$166,046	\$158,021	\$258,773
8	30.0	13	\$196,236	\$186,752	\$305,822
9	34.2	15	\$226,426	\$215,483	\$352,872
10	38.5	17	\$256,616	\$244,214	\$399,922
11	44.7	19	\$286,807	\$272,945	\$446,971
12	49.3	21	\$316,997	\$301,676	\$494,021
13	55.1	24	\$362,282	\$344,772	\$564,595
14	59.6	26	\$392,472	\$373,504	\$611,645
15	63.4	27	\$407,567	\$387,869	\$635,170
16	65.3	28	\$422,662	\$402,235	\$658,694
17	67.0	29	\$437,757	\$416,600	\$682,219
18	69.7	30	\$452,852	\$430,966	\$705,744
19	70.1	30	\$452,852	\$430,966	\$705,744
20-29	74.5	32	\$483,043	\$459,697	\$752,794
30-49	79.4	34	\$513,233	\$488,428	\$799,843
			\$513,233		
50-59	80.0	34	¢E12 222	\$488,428	\$799,843
60-69	79.8	34	\$513,233	\$488,428	\$799,843
70-79	76.6	33	\$498,138	\$474,062	\$776,318
80+	68.5	29	\$437,757	\$416,600	\$682,219

^a We used the case definition developed by the Evidence Review Workgroup for the ACHDNC to determine eligibility for ERT: Affected subjects have GAA enzyme activity <5% confirmed in leukocytes, fibroblasts, or muscle and have at least one pathologic mutation (i.e., not mutations associated with pseudodeficiency) on each allele. We chose to accept enzyme activity < 5% although the true enzyme activity level for those with the infantile-onset Pompe disease is typically much lower (i.e., <1%). However, some assays may not be able to detect enzyme activity that low, and therefore are only able to report <5%. In addition to low GAA enzyme activity, affected infants must have hypertrophic cardiomyopathy or muscle weakness before 1 year of age. Those with hypertrophic cardiomyopathy or significant cardiomegaly were classified as having classic infantile-onset Pompe disease. Otherwise, subjects were classified as having nonclassic infantile-onset Pompe disease. Identification of mutations known to be associated with Pompe disease can be supportive of the diagnosis. ¹⁴

Because GAA enzyme activity is not consistently reported, individuals were also considered to have infantile-onset Pompe disease if the GAA was reported to be low during the newborn period with associated cardiomyopathy or weakness and had mutations associated with infantile-onset Pompe disease.

^bRepresents 95% of the CDC Anthropometric Reference Data for Children and Adults: United States, 2007-2010¹⁵. ^cEach unit is 50 mg; total number of units is calculated as average weight x 20 mg/kg rounded up to the nearest unit.

^dWholesale acquisition cost ² with a 23% discount was used for a cost of \$580.54 per 50 mg unit.

e\$552.52 per 50 mg unit; government-negotiated price for VA, DoD, Bureau of Indian Affairs, and Coast Guard.

f\$904.80 per 50 mg unit-average wholesale price 2.

d. Costs of immune tolerance induction and enzyme replacement treatment

Variable	Base	Low	Upper	Source
Immune tolerance induction				
Methotrexate, 50mg (2ml and 25 mg/ml)	\$4	\$2	\$5	2
Rituximab, 100mg (10 ml and 10 mg/ml)	\$774	\$655	\$964	
Gammagard S/D, 5000mg (IGA<1ug/ml)	\$844	\$283	\$1,012	
Number of doses of methotrexate for one session of ITI	9	-	-	
Doses of rituximab required for 1 session of ITI	4	-	-	
Doses of IVIG required for 1 session of ITI	2	-	-	
Rituximab dose(mg/m^2) if BSA<0.5	12.5	-	-	
Rituximab dose (mg/m^2) if BSA <u>></u> 0.5	375	-	-	
IVIG dose (mg/kg)	450	-	-	
Provider visit to receive a methotrexate injection	\$133	-	-	
Rituximab infusion, hospital (1-2 h)	\$263	\$89	\$338	16
IVIG infusion, hospital (1-2 h)	\$263	\$89	\$338	2
Probability of requiring 2nd session of ITI at 5 months	0	0	0.5	Assumption
Proportion of infantile-onset Pompe disease receiving ITI (% CRIM negative)	0.25	0.2	0.5	17
Proportion of weight for Pompe disease patients compared to the national average weight by age	0.95	0.9	1	Assumption
Average BSA ^a	varies by age	0.288	2.014	15
Enzyme replacement therapy				
Infusion into a vein, up to 1 hour ^b	\$143	\$0	\$21,564	¹⁸ , Primary data analysis
Infusion into a vein, each additional hour ^c	\$86	\$0	\$1,670	
Estimated length of ERT infusion at hospital	6 hours	-	-	Assumption
Total costs for hospital infusions	\$550	\$166	\$15,000 ^d	
Home infusion, per visit, up to 2 hours ^e , or each additional hour ^f	\$110	\$48	\$250	¹⁸ , Primary data analysis
Estimated length of ERT infusion at home	6 hours	-	-	Assumption
Total costs for home infusions	\$558	\$135 ^g	\$4,000 ^d	
Percent of infusions at home (1st year infantile)	50%			Assumption
Percent of infusions at home (after 1st year)	100%			

<u>Abbreviations:</u> IGA, immune globulin antibodies; ITI, immune tolerance induction; IVIG, intravenous immunoglobulin; BSA, body surface area; CRIM, cross-reactive immunological material; ERT, enzyme replacement therapy.

^a BSA conversion formula: 0.024265*(height^0.3964) *(weight^{0.5378)}

^b CPT 96365

^c CPT 96366

^d Estimate from expert opinion

e CPT 99601

^f CPT 99602

g Estimate assumes an 82% ratio of home infusion to hospital infusion costs²

e. Annual medical expenditures, non-Pompe disease related⁴

Age	Medical Expenditures
<26	\$1,162
26-34	\$2,887
35-44	\$4,076
45-54	\$4,931
55-64	\$5,513
65-74	\$6,014
75+	\$5,967

f. Medical costs, Pompe disease

Medical Services	Cos t	Service s per Year	Lowe r Est.	Upper Est.	Total Annua I Costs	Lower Bound	Upper Bound	Source
Mild Pompe disease					. 00010			
Outpatient Visits								
Standard outpatient visit ^a	\$12 9	2	1	6	\$258	\$129	\$773	7, 1, Expert opinion
Physical therapy (adults only) ^b	\$35	12	6	24	\$423	\$211	\$845	opon
Occupational therapy (adults only) ^b	\$35	12	6	24	\$423	\$211	\$845	
Speech therapy ^c	\$84	12	6	24	\$1,002	\$501	\$2,00 5	
Nutritional therapy ^d	\$34	2	1	6	\$68	\$34	\$204	
Orthotics ^e	\$38	1	0	2	\$38	\$0	\$77	
Emergency visits								1, Expert
Emergency outpatient visit ^a	\$12 9	1	1	2	\$129	\$129	\$258	opinion
Additional procedures								7,1, Expert
Cardio/pulmonary consultation before exercise ^f	\$78 2	0.33	0.25	0.5	\$258	\$196	\$391	opinion
12-lead electrocardiogram with interpretation and report ^g	\$17	1	1	1	\$17	\$17	\$17	
Pulse oximetry, heart rate, perceived exertional effort ^h	\$3	4	2	6	\$13	\$6	\$19	
Limited overnight monitoring with pulse oximetry	\$25	1	1	1	\$25	\$25	\$25	
Full polysomnography ^j	\$61 0	0	0	0.25	\$0	\$0	\$152	
Capnography ^k	\$8	1	0	2	\$8	\$0	\$15	
Pulmonary function tests ¹	\$37	1	0.5	4	\$37	\$18	\$147	
Inhaled bronchodilators with airway clearance techniques, assisted coughing maneuvers ^m	\$92	1	0.5	2	\$92	\$46	\$185	
Oral stimulation & non- nutritive sucking ⁿ	\$80	0.25	0	0.5	\$20	\$0	\$40	
Videofluoroscopic swallowing test ^o	\$88	0.25	0	0.5	\$22	\$0	\$44	
Fall Risk assessment ^p	\$33	1	0.5	2	\$33	\$17	\$67	
Tympanometry ^q	\$13	0.5	0	1	\$6	\$0	\$13	
Auditory evoked potentials, comprehensive ^r	\$13 7	0.5	0	1	\$68	\$0	\$137	
Air and bone audiometrys	\$37	0.5	0	1	\$19	\$0	\$37	
Laboratory tests Creatine kinase-MB ^t	\$12	1	1	1	\$12	\$12	\$12	5, Expert opinion

Medical Services	Cos t	Service s per Year	Lowe r Est.	Upper Est.	Total Annua I Costs	Lower Bound	Upper Bound	Source
Comprehensive Panel ^u	\$19	1	1	1	\$19	\$19	\$19	Expert opinion
Urine Hex4	\$14 8	1	1	1	\$148	\$148	\$148	Expert opinion, personal communicati on ^v

f cont. Medical costs, Pompe disease

		Servi					Costs	
Medical Services	Cost	ces	Lowe	Upper	Total Annua	Costs - Lower	-	Source
		per Year	r Est.	Est.	I Costs	Est.	Upper Est.	
Medications								
Metoclopramide, child ^w	-	-	-	-	\$2,116	-	-	2, Expert
Metoclopramide, adult ^x	-	-	-	-	\$4,231	-	-	opinion
Ranitidine, child ^y	-	-	-	-	\$5,578	-	-	
Ranitidine, adult ^z	-	-	-	-	\$5,976	-	-	
Reflux medication, average, child	-	-	-	-	\$3,847	-	-	
Reflux medication, average, adult	-	-	-	-	\$5,104	-	-	
Severe Pompe disease								
Outpatient visits								
Standard outpatient visit ^a	\$130	8	6	10	\$1,039	\$779	\$1,29 9	7, 1, Expert opinion
Physical therapy ^b	\$35	52	48	52	\$1,831	\$1,69 0	\$1,83 1	
Occupational therapy ^b	\$35	52	48	52	\$1,831	\$1,69	\$1,83	
	604		40		64.244	0	1	
Speech therapy ^c	\$84	52	48	52	\$4,344	\$4,01 0	\$4,34 4	
Nutritional therapy ^d	\$34	8	6	10	\$272	\$204	\$340	
Oral function therapy ^{aa}	\$87	1	0	2	\$87	\$0	\$174	
Emergency visits	70.	_		_	ψο.	70	7-7	
Emergency outpatient visit ^a	\$130	2	1	2	\$260	\$130	\$260	1, Expert opinion
Emergency room visit	\$1,000	0	0	2	\$0	\$0	\$2,00 0	Expert opinion, Primary data
Hospitalization ^{cc}	\$46,26 4	0.5	0	1	\$23,13 2	\$0	\$46,2 64	analysis ^{bb} ¹⁹ , Expert opinion
Additional procedures								
Cardio/pulmonary consultation before exercise ^f	\$782	0.5	0.5	0.5	\$391	\$391	\$391	11, 1, Expert opinion
Pulse oximetry, heart rate, perceived exertional effort ^h	\$3	8	8	8	\$26	\$26	\$26	
12-lead electrocardiogram with interpretation and report ^g	\$17	4	4	4	\$69	\$69	\$69	
Full polysomnography ^j	\$610	0.25	0.25	0.25	\$152	\$152	\$152	
Tympanometry ^q	\$13	0.5	0.5	0.5	\$6	\$6	\$6	
Auditory evoked potentials, comprehensive ^r	\$137	0.5	0.5	0.5	\$68	\$68	\$68	
Air and bone audiometrys	\$37	0.5	0.5	0.5	\$19	\$19	\$19	

Lab tests Creatine kinase-MB ^t	\$12	1	1	1	\$12	\$12	\$12	5, Expert opinion
Comprehensive Panel ^u Urine Hex4	\$19 \$148	1	1	1	\$19 \$148	\$19 \$148	\$19 \$148	Expert opinion, personal communication

f cont. Medical costs, Pompe disease

Medical Services	Cost	Services per Year	Lower Est.	Upper Est.	Total Annual Costs	Lower Est.	Upper Est.	Source
Equipment								
Ventilator equipment ^{dd}	-	-	-	-	\$10,008	\$10,008	\$10,008	13
Wheelchair equipment, 1st	-	-	-	-	\$5,426	\$4,182	\$8,525	10
year ^{ee}								
Tube feeding	-	-	-	-	\$30,217	\$18,694	\$51,546	20
Medications								
Reflux medications								
Metoclopramide, child ^w	-	-	-	-	\$2,116	-	-	2, Expert
Metoclopramide, adult ^x	-	-	-	-	\$4,231	-	-	opinion
Ranitidine, child ^y	-	-	-	-	\$5,578	-	-	
Ranitidine, adult ^z	-	-	-	-	\$5,976	-	-	
Reflux medication, average, child	-	-	-	-	\$3,847	-	-	
Reflux medication, average, adult	-	-	-	-	\$5,104	-	-	
Medications for								
cardiomyopathy Diuretics								
Furosemide ^{ff}	-	-	-	-	\$893	-	-	2, Expert
Chlorothiazide ^{gg}	-	-	-	-	\$341	-	-	opinion
Spironolactone ^{hh}	-	-	-	-	\$198	-	-	
Diuretics, average	-	-	-	-	\$478	-	-	
ACE-inhibitors								
Enalapril maleate ⁱⁱ	-	-	-	-	\$45	-	-	
Captopril ^{jj}	-	-	-	-	\$192	-	-	
Lisinopril ^{kk}	_	-	-	-	\$3	-	-	
ACE-inhibitor average	-	-	-	-	\$80	-	-	
Other cardiac drugs								
Carvedilol ^{II}	-	-	-	-	\$451	-	-	
Digoxin ^{mm}	-	-	-	-	\$530	-	-	

^a CPT 99215

^b CPT 97530

^cCPT 92507

^d CPT 97802

^e CPT 97760

^fCPT 78451

g CPT 93000

^h CPT 94760

ⁱ CPT 94762

^j CPT 95808

^k CPT 94770

¹CPT 94010

^m CPT 31725

ⁿ CPT 92610

[°]CPT 92610

^p CPT 97750

- ^q CPT 92567
- ^rCPT 92585
- ^s CPT 92553
- ^tCPT 82550
- ^u CPT 80053
- ^v Duke University Department of Pediatrics
- w 20 mg/day at \$0.29/mg (wholesale acquisition cost)
- * 40 mg/day at \$0.29/mg (wholesale acquisition cost)
- ^y 280 mg/day at \$0.05/mg (wholesale acquisition cost)
- ²300 mg/day at \$0.05/mg (wholesale acquisition cost)
- aa CPT 92526
- ^{bb} Adult emergency department visit, moderate severity. Primary data analysis of 2016 MarketScan data conducted in December 2016.
- ^{cc} DRG 207 Respiratory system diagnosis w ventilator support 96+ hours
- ^{dd} Derived from ventilator costs for person with Duchenne muscular dystrophy, adjusted to 2016 US dollars
- ^{ee} Wheelchair equipment costs assumed to be similar to patients with tetraplegia (C5-C8) AIS A B or C, inflated to 2016 US dollars. Annual medical equipment costs were assumed to be \$0 but with an upper estimate \$1,579. This upper estimate is derived from DeVivo et. al. (2011)¹⁰ for patients with a spinal cord injury resulting in incomplete motor function.
- ff 38 mg/day at \$0.06/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- gg 375 mg/day at \$0.001/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- hh 45 mg/day at \$0.01/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- ⁱⁱ 2 mg/day at \$0.08/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- ^{jj} 12 mg/day at \$0.04/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- kk 1 mg/day at \$0.01/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg²
- $^{\parallel}$ 6 mg/day at \$0.20/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg 2
- mm 0.2 mg/day at \$7.70/mg (wholesale acquisition cost)

g. Quality of life adjustments

Health State	Value	Range	Source
Mild symptoms with Pompe disease, <18y	0.799	0.750- 0.844	21
Mild symptoms with Pompe disease, ≥18 y	0.853	0.811- 0.892	
Severe symptoms with Pompe disease, 0-1 y	0.399	0.341- 0.457	
Severe symptoms with Pompe disease, 2-17 y	0.466	0.407 - 0.525	
Severe symptoms with Pompe disease, ≥18 y	0.536	0.480- 0.594	
QALY loss due to transient positive screen	-0.0005		22
Spillover QALY loss among	-0.072	-0.042, -	
caregivers of child with mild symptoms		0.103	21
Spillover QALY loss among	-0.131	-0.090, -	
caregivers of child with		0.173	
severe symptoms, no			
cardiomyopathy			
Spillover QALY loss among	-0.18	-0.129, -	
caregivers of child with		0.230	
severe symptoms,			
cardiomyopathy			

- [1] Physician Fee Schedule [cited December 2016] Available from:
- http://www.cms.hhs.gov/PhysicianFeeSched/
- [2] Truven Health Analytics. Micromedex Solutions- Redbook. 2016.
- [3] Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev. 2017;11:CD011539.
- [4] US Bureau of Labor Statistics. Consumer Expenditure Survey [cited 2017 December 19th] Available from: https://www.bls.gov/cex/
- [5] Clinical Laboratory Fee Schedule [cited 2016 December] Available from:
- https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html
- [6] Ray KN, Chari AV, Engberg J, Bertolet M, Mehrotra A. Opportunity costs of ambulatory medical care in the United States. Am J Manag Care. 2015;21:567-74.
- [7] Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267-88.
- [8] Kanters TA, Hagemans ML, van der Beek NA, Rutten FF, van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis. 2011;34:1045-52.
- [9] Bureau of Labor Statistics. Current employment statistics [cited 2017 February 14] Available from: www.bls.gov/we/empsit/ceseesummary.htm
- [10] DeVivo M, Chen Y, Mennemeyer S, Deutsch A. Costs of care following spinal cord injury. Top Spinal Cord Inj Rehabil. 2011;16:1-9.

- [11] Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671-6.
- [12] National Center for Vital and Health Statistics. Anthropometric reference data for children and adults: United States 2007-2010. 2012.
- [13] Bach JR, Tran J, Durante S. Cost and physician effort analysis of invasive vs. noninvasive respiratory management of Duchenne muscular dystrophy. Am J Phys Med Rehabil. 2015;94:474-82.
- [14] Kemper AR, Comeau AM, Green NS, Goldenberg A, Ojodu J, Prosser LA, et al. Evidence report: newborn screening for pompe disease [cited 2018 November] Available from:
- https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf
- [15] Fryar CD, Gu Q, Ogden CL. Anthropometric Reference Data for Children and Adults: United States, 2007-2010. Vital Health Statistics. 2012;11:1-48.
- [16] Fair Health Consumer. [cited 2016 December] Available from: https://www.fairhealthconsumer.org/
- [17] Kemper AR, Browning M. Evidence Review: Pompe Disease [cited 2018 November 28] Available from: https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-evidence-review-report-2008.pdf
- [18] Truven Health Analytics. MarketScan. 2016.
- [19] Agency for Healthcare Research and Quality. Healthcare cost and utilization project [cited 2016 Available from: www.HCUPnet.ahrq.gov
- [20] Williams KE RK, Gibbons B, Field DG Intensive behavioral treatment for severe feeding problems: A cost-effective alternative to tube-feeding? . J Dev Phys Disabil. 2007;19:227-35.
- [21] Simon NJ, Richardson J, Ahmad A, Rose A, Wittenberg E, D'Cruz B, et al. Health utilities and parental quality of life effects for three rare conditions tested in newborns. J Patient Rep Outcomes. 2019;3:4.
- [22] Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med. 2008;162:870-6.

Table S3. Summary results, including family spillover, discounted

a. Health sector perspective, spillover included for all ages

Strategy	Costs	QALYs	Incremental	Incremental	\$/QALY ^a
			Costs	QALYs	
Clinically diagnosed,	\$72,916	30.45150			
untreated					
Clinically diagnosed,	\$72,986	30.45161	\$71	0.00011217	\$630,231
treated					
Screened, treated	\$73,042	30.45172	\$56	0.00011493	\$483,492

b. Societal perspective, spillover included for all ages

Strategy	Costs	QALYs	Incremental	Incremental	\$/QALY ^a
			Costs	QALYs	
Clinically diagnosed,	\$72,917	30.45150			
untreated					
Clinically diagnosed,	\$72,995	30.45161	\$78	0.00011217	\$692,232
treated					
Screened, treated	\$73,047	30.45172	\$53	0.00011493	\$457,345

c. Health sector perspective, spillover included for children only

Strategy	Costs	QALYs	Incremental	Incremental	\$/QALY ^a
			Costs	QALYs	
Clinically diagnosed,	\$72,916				
untreated		30.45150			
Clinically diagnosed,	\$72,986		\$71		
treated		30.45162		0.000119458	\$591,758
Screened, treated	\$73,042	30.45173	\$56	0.000117214	\$477,898

d. Societal perspective, spillover included for children only

Strategy	Costs	QALYs	Incremental	Incremental	\$/QALY ^a
			Costs	QALYs	
Clinically diagnosed,	\$72,917				
untreated		30.45150			
Clinically diagnosed,	\$72,995		\$78		
treated		30.45162		0.000119458	\$655,774
Screened, treated	\$73,047	30.45173	\$53	0.000116277	\$452,053

Abbreviations: QALYs, quality adjusted life years

^a Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

Table S4. Impact Inventory

Type of impact	Healthcare sector perspective	Societal perspective
Formal healthcare sector	· •	
Health outcomes		
Longevity effects		\square
ERT treatment extends life; newborn screening allows for an earlier start		
to treatment and better health outcomes		
Health related quality of life effects	$\overline{\checkmark}$	
ERT treatment reduces disease progression, improving quality of life		
Other health effects		
Spillover impact on caregivers' health related quality of life were		
included in a sensitivity analysis		
Medical costs		
Medical costs paid by third-party payers		
Included costs of provider visits, procedures, labs etc.		
Medical costs paid for out-of-pocket		
Out-of-pocket costs were not included		
Future related medical costs		
Patients who survive longer incur costs related to ERT and other Pompe		
disease-related medical services		
Future unrelated medical costs		
Patients who survive longer incur medical expenditures not specific to		
Pompe disease		
Informal healthcare sector		
Patient time costs		
Included for each Pompe disease-related provider visit among those with		
no/mild symptoms. Not included for those with severe symptoms as		
patient would not be able to engage in productive activities (market or		
non-market).		
Unpaid caregiver costs		\square
Included, differential for mild and severe disease states		
Transportation costs		
Not included		
Non-healthcare sectors		
Productivity losses		
Not included		
Consumption		
Not included		
Cost of social services		
Pompe disease has not been associated with cognitive impairment;		
education costs and other social services not included	_	_
Cost of crimes related to intervention		
Not applicable to condition		

Abbreviations: ERT, enzyme replacement therapy.

Table S5. Transition probabilities and treatment effectiveness

a. Clinically diagnosed, untreated

				Pompe disease
	No symptoms	Mild	Severe	death
Infantile-onset with cardiomyopathy				
No symptoms	-	-	-	-
Mild		0.2240	0.1450	0.6310
Severe			0.0070	0.9930
Infantile-onset without cardiomyopathy				
No symptoms	-	-	-	-
Mild		0.9399	0.0237	0.0364
Severe			0.9330	0.0670

b. Clinically diagnosed, treated

				Pompe disease
	No symptoms	Mild	Severe	death
Infantile-onset with cardiomyopathy, age <5 ^a				
No symptoms	-	-	-	-
Mild		0.9667	0.0334	0.0000
Severe			0.7716	0.2284
Infantile-onset with cardiomyopathy, age ≥5 ^b				
No symptoms	-	-	-	-
Mild		0.9323	0.0677	0.0000
Severe			0.9460	0.0540
Infantile-onset without cardiomyopathy, all ages ^c				
No symptoms	-	-	-	-
Mild		0.9962	0.0038	0.0000
Severe			0.9893	0.0107

^a Treatment effectiveness relative to untreated: 0.770

^b Treatment effectiveness relative to untreated: 0.930

^c Treatment effectiveness relative to untreated: 0.840

c. Screened, treated

				Pompe disease
	No symptoms	Mild	Severe	death
Infantile-onset with cardiomyopathy ^a				
No symptoms	0.9993	0.0007	0.0000	0.0000
Mild		0.9993	0.0007	0.0000
Severe			0.9950	0.0050
Infantile-onset without cardiomyopathya				
No symptoms	0.9999	0.0001	0.0000	0.0000
Mild		0.9999	0.0001	0.0000
Severe			0.9997	0.0003
Late-onset (all scenarios) ^b				
No symptoms	0.9801	0.0130	0.0060	0.0009
Mild		0.9690	0.0300	0.0010
Severe			0.9990	0.0010

^a Treatment effectiveness relative to untreated: 0.995

^b Treatment effectiveness relative to untreated: 0.000 (no one is treated)

Table S6. Undiscounted summary results, base case

a. Health sector perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALYª
Clinically diagnosed, untreated	\$288,244	79.12927			
Clinically diagnosed, treated	\$288,436	79.12959	\$193	0.00031325	\$615,063
Screened, treated	\$288,622	79.12993	\$186	0.00034880	\$533,265

b. Societal perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALYª
Clinically diagnosed, untreated	\$288,246	79.12927			
Clinically diagnosed, treated	\$288,455	79.12959	\$209	0.00031325	\$666,966
Screened, treated	\$288,637	79.12993	\$182	0.00034880	\$521,751

Abbreviations: QALYs: quality adjusted life years

^a Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

Table S7. Discounted summary results, base case

a. Health sector perspective

Strategy	Cost	QALYs	Incrementa I Costs	Incremental QALYs	\$/QALYª
Clinically diagnosed,	\$72,916	30.45150			
untreated					
Clinically diagnosed, treated	\$72,986	30.45163	\$71	0.00012700	\$556 <i>,</i> 788
Screened, treated	\$73,042	30.45174	\$56	0.00011387	\$488,015

b. Societal perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY ^a
Clinically diagnosed, untreated	\$72,917	30.45150			
Clinically diagnosed, treated	\$72,995	30.45167	\$78	0.00012696	\$611,564
Screened, treated	\$73,047	30.45174	\$53	0.00011387	\$461,623

Abbreviations: QALYs, quality adjusted life years

^a Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

Table S8. Undiscounted disaggregated costs and QALYs, annual newborn cohort of 4,000,000

Category	Clinically	Clinically	Screened,
	diagnosed,	diagnosed, treated	treated
	untreated		
Screening/confirmation	\$0	\$0	\$26,247,508
ERT, including delivery/ITI	\$0	\$712,398,660	\$1,456,117,610
Medical costs, Pompe disease	\$4,511,991	\$35,776,216	\$24,064,327
related			
Medical costs, non-Pompe	\$291,670,590,439	\$291,675,998,489	\$291,691,376,995
disease related			
Informal care	\$7,467,819	\$69,604,014	\$51,522,054
Formal care	\$3,283,071	\$24,882,884	\$4,706,816
Non-medical costs	\$1,830,181	\$4,728,447	\$6,745,913
(environmental modification,	71,030,101	74,720,447	Ş0,743,913
appointment time costs)			
Undiscounted QALYs	316,517,089	316,518,342	316,519,737

Abbreviations: ERT, enzyme replacement therapy; ITI, immune tolerance induction; QALYs, quality adjusted life years.

Table S9. One-way sensitivity analyses

Input		Strategy	Cost	QALY	Incremental Cost	Incremental QALY	ICER ^a
Screeni	ing test cost	,					
Low	\$1.00	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
		Screened, treated	\$73,042	30.45174	\$47	0.000114	\$414,258
High	\$17.50	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.451626	\$78	0.000127	\$611,564
		Screened, treated	\$73,058	30.45174	\$64	0.000114	\$559,106
Confirm	natory genet	ic test cost	_				
Low	\$1,140.00	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
		Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,572
High	\$1,768.00	Clinically diagnosed, untreated	\$72,917	30.45150	-		-
		Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
		Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,947
Other o	confirmatory	test cost					
Low	\$662.04	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
		Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,459
High	\$1,531.72	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
		Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,978
ERT cos	sts						
Lov	W	Clinically diagnosed, untreated	\$72,917	30.4515	-	-	-
		Clinically diagnosed, treated	\$72,982	30.451626	\$65	0.000126	\$510,906
		Screened, treated	\$73,024	30.45174	\$42	0.0001149	\$369,990
High		Clinically diagnosed, untreated	\$72,917	30.4515	-	-	
		Clinically diagnosed, treated	\$72,998	30.451626	\$81	0.000126	\$639,864
		Screened, treated	\$73,054	30.45174	\$56	0.0001149	\$489,321

Table 10. Sensitivity analysis, cost of alglucosidase alfa, societal perspective

Alglucosidase alfa, % of AWP	Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	ICER ^a
0%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$73,013	30.45163	\$96	0.00012696	\$757,191
	Screened, treated	\$73,081	30.45174	\$68	0.00011387	\$595,928
10%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$73,005	30.45163	\$88	0.00012696	\$693,875
	Screened, treated	\$73,066	30.45174	\$61	0.00011387	\$537,535
20%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,997	30.45163	\$80	0.00012696	\$630,559
	Screened, treated	\$73,051	30.45174	\$55	0.00011387	\$479,141
30%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,989	30.45163	\$72	0.00012696	\$567,243
	Screened, treated	\$73,037	30.45174	\$48	0.00011387	\$420,748
40%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,981	30.45163	\$64	0.00012696	\$503,927
	Screened, treated	\$73,022	30.45174	\$41	0.00011387	\$362,355
50%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,973	30.45163	\$56	0.00012696	\$440,610
	Screened, treated	\$73,007	30.45174	\$35	0.00011387	\$303,961
60%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,965	30.45163	\$48	0.00012696	\$377,294
	Screened, treated	\$72,993	30.45174	\$28	0.00011387	\$245,568
70%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,957	30.45163	\$40	0.00012696	\$313,978
	Screened, treated	\$72,978	30.45174	\$21	0.00011387	\$187,175
80%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,949	30.45163	\$32	0.00012696	\$250,662
	Screened, treated	\$72,963	30.45174	\$15	0.00011387	\$128,782
90%	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,941	30.45163	\$24	0.00012696	\$187,345
	Screened, treated	\$72,949	30.45174	\$8	0.00011387	\$70,388

Abbreviations: QALYs, quality adjusted life years; ICER, incremental cost effectiveness ratio.

^aIncremental comparisons are CI & treated vs. CI & untreated, and NBS treated vs. CI & treated.

Table S9 cont. One-way sensitivity analyses

Input		Strategy	Cost	QALY	Incr. Cost	Incr. QALY	ICER ^a
ERT deli	very cost						
Low	\$10,882	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,994	30.45163	\$77	0.000127	\$606,435
		Screened, treated	\$73,046	30.45174	\$52	0.000114	\$457,564
High	\$96,000	Clinically diagnosed, untreated	\$72,917	30.4515	-		-
		Clinically diagnosed, treated	\$73,010	30.45163	\$93	0.000127	\$734,174
		Screened, treated	\$73,074	30.45174	\$64	0.000114	\$558,657
Informa	l care hour	ly wage					
Low	\$17.74	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,992	30.45163	\$76	0.000127	\$595,307
		Screened, treated	\$73,046	30.45174	\$54	0.000114	\$470,220
High	\$25.71	Clinically diagnosed, untreated	\$72,917	30.4515	-		-
		Clinically diagnosed, treated	\$72,995	30.451626	\$78	0.000127	\$611,564
		Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,623
Health (utility weig	hts	-				
Low		Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
		Clinically diagnosed, treated	\$72,995	30.45162	\$78	0.000119	\$651,563
		Screened, treated	\$73,047	30.45173	\$53	0.000113	\$465,805
High		Clinically diagnosed, untreated	\$72,917	30.45150	-		-
		Clinically diagnosed, treated	\$72,995	30.45164	\$78	0.000134	\$578,137
		Screened, treated	\$73,047	30.45175	\$53	0.000115	\$458,461
Treatme	ent effectiv	reness					
Low		Clinically diagnosed, untreated	\$72,915	30.45179	-	-	-
		Clinically diagnosed, treated	\$72,915	30.45179	\$59	0.000099	\$599,269
		Screened, treated	\$72,922	30.45179	\$56	0.000110	\$506,131
High		Clinically diagnosed, untreated	\$72,915	30.45179	-	-	-
		Clinically diagnosed, treated	\$72,915	30.45179	\$89	0.000143	\$625,651
		Screened, treated	\$72,922	30.45179	\$40	0.000099	\$403,317

Abbreviations: Incr., incremental; QALYs, quality adjusted life years; ICER, incremental cost effectiveness ratio; ERT, enzyme replacement therapy.

^a Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health or via the ISPOR Health Economic Evaluation Publication Guidelines - CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

Section/item	Item No	Recommendation	Reported on page No/ line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	Pg 1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	Pg 3
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	
		Present the study question and its relevance for health policy or practice decisions.	Pg 4
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Pg 4
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Pg 4-6
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Pg 4
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Pg 5
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Pg 4
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Pg 7
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Pg 7
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	NA



Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data. If applicable, describe the population and methods used to elicit preference based outcomes				
valuation of preference based outcomes elicit preferences for outcomes. Pg 7 Estimating resources and costs 13a Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. NA 4 13b Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. Pg 6-7 Currency, price date, and conversion 14 Report the dates of the estimated resource quantities and unit costs. Describe methods for valuing each resource item in terms of its unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate. Pg 6-7 Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended. Pg 5-6 Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Pg 4-6 Analytical methods 17 Describe all analytical methods supporting the eva		11b	identification of included studies and synthesis of clinical	Pg 6
Estimating resources 13a Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. 13b	Measurement and	12	If applicable, describe the population and methods used to	
and costs used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. 13b Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. Currency, price date, and conversion 14 Report the dates of the estimated resource quantities and unit costs. Describe any adjustments made to approximate to opportunity costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate. Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended. Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model used. Providing a figure to show model structure is strongly recommended. Analytical methods 17 Describe all surfuctural or other assumptions underpinning the decision-analytical model. Describe all analytical methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Pg 7 Results Results Report the values, ranges, references, and, if used, probability distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Single study-based economic evalua	•			Pg 7
Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. Pg 6-7	_	13a	used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity	NA
Currency, price date, and conversion between the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate. Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended. Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Pg 7 Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty Tables 4, 9		13b	Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit	
and conversion costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate. Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended. Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and operations of interest, as well as mean differences between the comparator groups. If applicable, report incremental costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty NA				Pg 6-7
Choice of model 15 Describe and give reasons for the specific type of decision- analytical model used. Providing a figure to show model structure is strongly recommended. Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Pg 5-6 Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Pg 7 Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and 19 For each intervention, report mean values for the main outcomes Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty NA NA NA		14	costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for	
Choice of model 15 Describe and give reasons for the specific type of decision- analytical model used. Providing a figure to show model structure is strongly recommended. Pg 5-6 Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Pg 4-6 Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Pg 7 Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Tables 1-3 Incremental costs and 19 For each intervention, report mean values for the main outcomes categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Tables 4, 9 Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty of sampling uncertainty for the estimated incremental cost and			·	Pa 6 Table 3
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes 19 For each intervention, report mean values for the main outcomes 20 categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty NA	Choice of model	15	_	1 9 0, 14510 0
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty NA MA NA			analytical model used. Providing a figure to show model structure is strongly recommended.	Pg 5-6
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects uncertainty NA NA	Assumptions	16		D 4.0
Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and	Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half	Pg 4-6
Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and			•	D 7
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and			population heterogeneity and uncertainty.	Pg /
distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Incremental costs and outcomes Tables 1-3 Incremental costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and	Results			
Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and	Study parameters	18	distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate.	
outcomes categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. Characterising 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and				Tables 1-3
applicable, report incremental cost-effectiveness ratios. Characterising uncertainty 20a Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and		19	categories of estimated costs and outcomes of interest, as well	
uncertainty of sampling uncertainty for the estimated incremental cost and NA	Characterising	20a	applicable, report incremental cost-effectiveness ratios.	Tables 4, 9
			of sampling uncertainty for the estimated incremental cost and	NA



	20b	of methodological assumptions (such as discount rate, study perspective). Model-based economic evaluation: Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	Tables 11, 12 Figures 2, 3
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost- effectiveness that can be explained by variations between	
neurogeneity		subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	NA NA
Discussion			
Study findings, limitations,	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the	
generalisability, and current knowledge		generalisability of the findings and how the findings fit with current knowledge.	Pg 9-12
Other			
Source of funding	23	Describe how the study was funded and the role of the funder	
		in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Pg 1
Conflicts of interest 2		Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Pg 1

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.

